Abstract
A multitude of tests are available for the diagnosis and management of the vasculitides. Most of them are nonspecific but provide useful information that, when appropriately used in conjunction with the patient’s history and physical examination can be of great assistance in arriving at a final diagnosis. In addition, information gathered may be of great help in monitoring disease activity and clinical response to therapy, in indicating the presence of specific organ system involvement, in monitoring toxicity of medication used, and in assessing prognosis. Serial measurements of acute phase reactants, complete blood cell count with differential, biochemistry profiles, urinalysis, and C3 and C4 levels should be obtained in all patients. Antineutrophil cytoplasmic antibodies (ANCA) determination provides valuable information and is highly specific for the diagnosis of small-vessel vasculitides, particularly Wegener’s granulomatosis and microscopic polyangiitis. ANCA levels can be particularly useful to assess disease activity in these disorders. Hepatitis-B and, more importantly, hepatitis-C testing is extremely useful, particularly in the presence of liver involvement and associated risk factors. Angiographic studies may confirm the diagnosis, particularly if there is laboratory and clinical evidence of specific organ involvement. It should be noted, however, that angiography may be normal even when vasculitis is present, or the findings may be nonspecific. A definite diagnosis is provided by a tissue biopsy. This should be performed whenever there is access to clinically affected tissue.
Similar content being viewed by others
References and Recommended Reading
Bowles CA: Laboratory tests in rheumatology: practical considerations. Rheumatol Musculosk Med Prim Care 1999, 1:3–4.
Wener MH: Rheumatology laboratory tests. Rheumatol Musculosk Med Prim Care 1999, 1:1–5.
Merkel PA, Polisson RP, Chang Y, et al.:Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997, 126:866–873. Good study regarding prevalence of ANCA in connective tissue disorders.
Cohen MD, Conn DL: Approach to the patient with suspected vasculitis. Bull Rheum Dis 1999, 42:1–4.
Grau GE, Roux-Lombard P, Gysler C, et al.:Serum cytokine changes in systemic vasculitis. Immunology 1989, 68:196–198.
McMurray RW: Hepatitis C-associated autoimmune disorders. Rheum Dis Clin North Am 1998, 24:353–374. A good review of Hepatitis C-associated rheumatic disorders including mixed cryoglobulinemia.
Asherson RA, Cervera R: The antiphospholipid syndrome: a syndrome in evolution. Ann Rheum Dis 1992, 51:147–150.
Espinoza LR, Jara LJ, Silveira L, et al.:Anticardiolipin antibodies in polymyalgia-rheumatica-giant cell arteritis. Am J Med 1991, 90:474–478.
Duhaut P, Berruyer M, Pinede L, et al.:Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter casecontrolled study. Arthritis Rheum 1998, 41:701–709.
Hansen KE, Moore KD, Ortel TL, Allen NG: Antiphospholipid antibodies in patients with Wegener’s granulomatosis and polyarteritis nodosa. Arthritis Rheum 1999, 42:2250–2251.
Jennette JC, Falk RJ: Disease associations and pathogenic role of antineutrophil cytoplasmic autoantibodies in vasculitis. Curr Opin Rheum 1992, 4:9–15.
Choi HK, Merkel PA, Tervaert JW, et al.:Alternating antineutrophil cytoplasmic antibody specialty: drug-induced vasculitis in a patient with Wegener’s granulomatosis. Arthritis Rheum 1999, 42:384–388.
Harris A, Chang G, Vadas M, Gillis D: ELISA is the superior method for detecting antineutrophil cytoplasmic antibodies in the diagnosis of systemic necrotizing vasculitis. J Clin Pathol 1999, 52:670–676.
Hagen CH, Daha MR, Hermans J, et al.:The diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies (ANCA) in idiopathic systemic vasculitis. Kidney Int 1997, 53:743–753. Useful study demonstrating the value of standardized assays for ANCA in the diagnosis of systemic vasculitis.
Savige J, Gillis D, Benson E, et al.:International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999, 111:507–513. A very good set of guidelines on testing and interpretation of ANCA testing.
Lim LCL, Taylor JG, Schimtz JL, et al.:Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology: comparative evaluation of commercial indirect fluorescent antibody kits and enzyme immunoassays kits. Am J Clin Pathol 1999, 111:363–369. Useful study with practical applications on commercially available kits for ANCA testing.
Ara J, Eduardo M, Rodriguez R, et al.:Relationship between ANCA and disease activity in small-vessel vasculitis patients with anti-MPO ANCA. Nephrol Dial Transplant 1999, 14:1667–1672. Very good clinical study demonstrating the value of ANCA testing in relation to disease activity in small vessel vasculitis.
Federici AB, Fox RI, Espinoza LR, Zimmerman TS: Giant cell arteritis: elevation of von Willebrand factor is independent of erythrocyte sedimentation rate and persists after steroid treatment. Arthritis Rheum 1984, 24:1046–1048.
Li CG, Reynolds I, Ponting JM, et al.:Serum levels of vascular endothelial growth factor (VEGF) are markedly elevated in patients with Wegener’s granulomatosis. Br J Rheumatol 1998, 37:1303–1306.
Boffa MC, Karmochkine M: Thrombomodulin: an overview and potential implications in vascular disorders. Lupus 1998, 2:S120–125.
Csernok E, Trabandt A, Muller A, et al.:Cytokine profiles in Wegener’s granulomatosis: predominance granulomatosis: predominance of type I (Th1) in the granulomatosis inflammation. Arthritis Rheum 1999, 42:742–750.
Frassanito MA, Dammacco R, Cafforio P, Dammacco F: Th1 polarization of the immune response in Behcet’s disease. Arthritis Rheum 1999, 42:1967–1974.
Noris M, Daina E, Gambas S, et al.:Interleukin-6 and RANTES in takayasu arteritis: a guide for therapeutic decisions? Circulation 1999, 100:55–60.
Uchio E, Matsumoto T, Tanaka SI, Ohno S: Soluble intercellular adhesion molecule-1 (ICAM-1), CD4, CD8 and interleukin-2 receptor in patients with Behcet’s disease and Vogt-Koyanagi-Harada’s disease. Clin Exp Rheumatol 1999, 17:179–184.
Zaman AG, Edelsten C, Stanford MR, et al.:Soluble intercellular adhesion molecule-1 (ICAM-1) as a marker of disease relapse in idiopathic uveoretinits. Clin Exp Immunol 1994, 95:60–65.
Bernacchi E, Cirita LL, Caproni M, et al.:Hepatitis C virus (HCV) in cryoglo-bulinemic leukocytoclastic vasculitis (LCV): could the presence of HCV in skin lesions be related to T CD8+ lymphocytes, HLA-DR and ICAM-1 expression? Exp Dermatol 1999, 8:480–486.
Fernandes SR, Bertolo MB, Rossi CL, et al.:Polyarteritis nodosa and cytomygolo-virus: diagnosis by polymerase chain reaction. Clin Rheumatol 1999, 18:501–503.
Aksu K, Kabasakal Y, Sayiner A, et al.:Prevalences of hepatitis A, B, C, and E viruses in Behcet’s disease. Rheumatology 1999, 38:1279–1281.
Stenson AW: Roentgenographic findings in major vasculitc syndromes. Rheum Dis Clin North Am 1990, 16:293–308. Very good review on typical angiographic findings in systemic vasculitis.
Avrigucci S, Fantozzi G, Riello F, et al.:Horton’s temporal arteritis: diagnosis using color Doppler ultrasonography. Minverva Cardioangiol 1998, 46:345–346.
Jennette CJ, Milling DM, Falk RJ: Vasculitis affecting the skin. A review. Arch Dermatol 1994, 130:899–906.
Alrawi A, Trobe JD, Blaivas M, Musch DC: Brain biopsy in primary angiitis of the central nervous system. Neurology 1999, 53:858–860.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cuellar, M.L., Espinoza, L.R. Laboratory testing in the evaluation and diagnosis of vasculitis. Curr Rheumatol Rep 2, 417–422 (2000). https://doi.org/10.1007/s11926-000-0042-6
Issue Date:
DOI: https://doi.org/10.1007/s11926-000-0042-6